Poliomyelitis and Poliovirus Immunization

John F. Modlin

doi:10.1128/9781555818326.ch9

Chapter 9 : Poliomyelitis and Poliovirus Immunization

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Departments of Pediatrics and Medicine, Dartmouth Medical School, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756

Content Type: Monograph

Publication Year: 1995

Category: Clinical Microbiology; Viruses and Viral Pathogenesis

Book DOI: 10.1128/9781555818326

Chapter DOI: 10.1128/9781555818326.ch9

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Poliomyelitis and Poliovirus Immunization, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555818326/9781555810924_Chap09-1.gif /docserver/preview/fulltext/10.1128/9781555818326/9781555810924_Chap09-2.gif

Abstract:

Poliomyelitis is an acute, febrile illness characterized by aseptic meningitis and weakness or paralysis of one or more extremities. This chapter reviews the historical background, pathophysiology, and clinical manifestations of poliomyelitis. It also reviews current issues regarding both inactivated and live, attenuated poliovirus vaccines. The clinical, epidemiologic, and scientific foundations for the control of poliomyelitis were laid in the first half of the 20th century, and eradication has since been achieved through routine immunization programs that use two very effective vaccines, each of which possesses unique advantages and disadvantages.

Citation: Modlin J. 1995. Poliomyelitis and Poliovirus Immunization, p 195-220. In Rotbart H (ed), Human Enterovirus Infections. ASM Press, Washington, DC. doi: 10.1128/9781555818326.ch9

Highlighted Text: Show | Hide

Full text loading...

References

/content/book/10.1128/9781555818326.chap9

1. Abercrombie, J. 1828. Pathological and Practical Researches on Diseases of the Brain and Spinal Cord. Waugh and Innes, Edinburgh.

2. Almond, J. W. 1987. The attenuation of poliovirus neurovirulence. Annu. Rev. Microbiol. 41: 154– 180.

3. Almond, J. W.,, G. D. Westrop,, D. M. Evans, et al. 1987. Studies on the attenuation of the Sabin type 3 oral polio vaccine. J. Virol. Methods 17: 183– 189.

4. Anderson, G. W.,, G. Anderson,, and A. Skaar. 1952. Poliomyelitis in pregnancy. Am. J. Hyg. 55: 127.

5. Anderson, J. F.,, and W. H. Frost. 1911. Abortive cases of poliomyelitis: an experimental demonstration of specific immune bodies in their blood-serum. JAMA 56: 633– 639.

6. Armstrong, C. 1939. The experimental transmission of poliomyelitis to the eastern cotton rat, Sigmodon hispidus hispidus. Public Health Rep. 54: 1719– 1721.

7. Armstrong, C. 1939. Successful transfer of the Lansing strain of poliomyelitis virus from the cotton rat to the white mouse. Public Health Rep. 54: 2302– 2305.

8. Bass, J. W.,, S. B. Halsted,, and G. W. Fischer. 1978. Oral polio vaccine: effect of booster vaccination one to 14 years after primary series. JAMA 239: 2252– 2255.

9. Benyesh-Melnick, M. 1967. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am. J. Epidemiol. 86: 112– 136.

10. Bijkerk, H. 1979. Poliomyelitis epidemic in the Netherlands. Dev. Biol. Stand. 43: 195– 206.

11. Bodian, D. 1949. Histopathologic basis of the clinical findings in poliomyelitis. Am. J. Med. 6: 563.

12. Bodian, D. 1952. Pathogenesis of poliovirus in normal and passively immunized primates after virus feeding. Fed. Proc. 11: 462.

13. Bodian, D. 1954. Viremia in experimental poliomyelitis. II. Viremia and the mechanism of the "provoking" effect of injections or trauma. Am. J. Hyg. 60: 358.

14. Bodian, D. 1954. Viremia in experimental poliomyelitis. I. General aspects of infection after intravascular inoculation with strains of high and low invasiveness. Am. J. Hyg. 60: 339.

15. Bodian, D. 1955. Emerging concepts of poliomyelitis infection. Science 122: 105.

16. Bodian, D. 1956. Poliovirus in chimpanzee tissues after virus feeding. Am. J. Hyg. 64: 187.

17. Bodian, D.,, and H. A. Howe. 1940. An experimental study of the role of neurones in the dissemination of poliomyelitis virus in the nervous system. Brain 63: 135.

18. Bodian, D.,, I. M. Morgan,, and H. A. Howe. 1949. Differentiation of three types of poliomyelitis virus. III. The grouping of fourteen strains into three immunological types. Am. J. Hyg. 49: 234.

19. Bottiger, M.,, S. Gard,, and B. Zetterberg. 1966. Vaccination with attenuated type 1 poliovirus, the Chat strain. II. Transmission of virus in relation to age. Acta Paediatr. Scand. 55: 416– 421.

20. Brodie, M. 1934. Active immunization in monkeys against poliomyelitis with germicidally inactivated virus. Science 79: 594– 595.

21. Brodie, M.,, S. A. Goldberg,, and P. Stanley. 1935. Transmission of the virus of poliomyelitis to mice. Science 81: 319.

22. Brodie, M.,, and W. H. Park. 1935. Active immunization against poliomyelitis. JAMA 105: 9.

23. Burnet, F. M.,, and J. Macnamara. 1931. Immunological differences between strains of poliomyelitic virus. Br. J. Exp. Pathol. 12: 57– 61.

24.Centers for Disease Control. 1982. Recommendations of the Immunization Practices Advisory Committee: poliomyelitis prevention. Morbid. Mortal. Weekly Rep. 31: 22– 26, 31– 34.

25.CentersforDiseaseControl. 1987. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine—supplementary statement. Morbid. Mortal. Weekly Rep. 36: 795– 798.

26. Charcot, J.-M. 1872. Groupe des myopathies de cause spinale; paralysie infantile. Rev. Phot. Hop. (Paris) 4: 1– 36.

27. Chen, R.,, M. Hanfling,, and S. Hausinger. 1992. Extent of secondary spread of oral polio vaccine virus spread in inner-city pre-school children, abst. 1403. Program Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother.

28. Chin, T. D.Y.,, and W. M. Marine. 1961. The changing pattern of poliomyelitis observed in two urban epidemics. Public Health Rep. 76: 553– 563.

29. Chin, T. D. Y.,, W. M. Marine,, and E. C. Hall. 1961. Poliomyelitis in Des Moines, Iowa, 1959. The influence of Salk vaccination on the epidemic pattern and spread of the virus in the community. Am. J. Hyg. 74: 67– 94.

30.Committee on Infectious Diseases, American Academy of Pediatrics. 1994. Report of the Committee on Infectious Diseases, 23rd ed. American Academy of Pediatrics, Elk Grove Village, III.

31. Cordier, S. 1988. Relation d'une épidemie de paralysie atrophique de l'enfance. Lyon Med. 48: 5– 12.

32. Cornil, V. 1863. Paralysie infantile; cancer les seins; autopsie; altérations de la moelle épinière, des nerfs et des muscles; généralisation du cancer. C. R. Soc. Biol. (Paris) 5: 187.

33. Cruz, R. R. 1984. Cuba: mass polio vaccination program, 1962-1982. Rev. Infect. Dis. 6( 2): 408– 412.

34. Dalakas, M. C.,, G. Elder,, and M. Hallet. 1986. A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms. N. Engl. J. Med. 314: 959– 963.

35. Dalakas, M. C.,, J. L. Sever,, and D. L. Madden. 1984. Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies. Rev. Infect. Dis. 6( 2): S562– S567.

36. Davis, L. E.,, D. Bodian,, and D. Price. 1977. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. N. Engl. J. Med. 297: 241.

37. de Brito Bastos, N. C.,, E. S. de Carvalho,, H. Schatzmayr,, A. Homma,, and J. Chaves. 1974. Antipoliomyelitis program in Brazil: a serologic study of immunity. Bull. PAHO 8: 54– 65.

38. DeForest, A. 1973. The effect of breast-feeding on the antibody response of infants to triva-lent oral poliovirus vaccine. J. Pediatr. 83: 93– 95.

39. Deming, M. S.,, K. O. Jaiteh,, and M. W. Otten. 1992. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease. II. Clinical efficacy of trivalent oral polio vaccine. Am. J. Epidemiol. 135: 393– 408.

40. Domok, I.,, M. S. Balayan,, and O. A. Fayinka. 1974. Factors affecting the efficacy of live poliovirus vaccine in warm climates. Bull. W.H.O. 51: 333– 347.

41. Dong, D.-X.,, X.-M. Hu,, W.-J. Liu, et al. 1986. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). Bull. W.H.O. 64: 853– 860.

42. Draper, G. 1935. Infantile Paralysis, 2nd ed. Appleton-Century, New York.

43. Drinker, P.,, and C. F. McKhann. 1929. The use of a new apparatus for the prolonged administration of artificial respiration; a fatal case of poliomyelitis. JAMA 92: 1658.

44. Drinker, P.,, and L. A. Shaw. 1929. Apparatus for prolonged administration of artificial respiration; design for adults and children. J. Clin. Invest. 7: 229.

45. Enders, J. F.,, T. H. Weller,, and F. C. Robbins. 1949. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science 109: 85– 87.

46. Enders, J. F.,, T. H. Weller,, and F. C. Robbins. 1952. Alterations in pathogenicity for monkeys of Brunhilde strain of poliovirus following cultivation in human tissues. Fed. Proc. 11: 467.

47. Evans, D. M.,, G. Dunn,, P. D. Minor, et al. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature (London) 314: 548– 550.

48.Expanded Programme on Immunization. 1985. Global Advisory Group. Weekly Epidemiol. Rec. W.H.O. 60: 13– 16.

49.Expanded Programme on Immunization. 1988. Poliomyelitis surveillance and vaccine efficacy. Weekly Epidemiol. Rec. WHO. 63: 249– 251.

50. Faden, H.,, J. F. Modlin,, M. L. Thorns,, A. M. McBean,, M. B. Ferndon,, and P. L. Ogra. 1990. Comparative evaluation of immunization with live attenuated and enhanced potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162: 1291– 1297.

51. Flexner, S.,, and P. F. Clark. 1912-1913. A note on the mode of infection in epidemic poliomyelitis. Proc. Soc. Exp. Biol. Med. 10: 1.

52. Flexner, S.,, and P. A. Lewis. 1909. The transmission of poliomyelitis to monkeys. JAMA 53: 1639.

53. Flexner, S.,, and P. A. Lewis. 1910. Experimental poliomyelitis in monkeys; active immunization and passive serum protection. JAMA 54: 1780.

54. Fox, J. P.,, L. Elveback,, and W. Scott. 1971. Herd immunity: basic concept and relevance to public health immunization practices. Am. J. Epidemiol. 94: 179– 189.

55. Frost, W. H. Epidemiologic studies of acute anterior poliomyelitis. Hyg. Lab. Bull. 90: 1913.

56. Gatmaitan, B. G.,, J. L. Chason,, and A. M. Lerner. 1970. Augmentation of the virulence of murine coxsackievirus B-3 myocardiopathy by exercise. J. Exp. Med. 131: 1121– 1136.

57. Gelfand, H. M.,, D. R. LeBlanc,, and J. P. Fox. 1957. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am. J. Hyg. 65: 367– 385.

58. Gelfand, H. M.,, D. R. LeBlanc,, and J. P. Fox. 1959. Studies on the development of natural immunity to poliomyelitis in Louisiana. III. The serologic response to commercially produced "Salk vaccine" of children totally or partially susceptible to poliovirus infection. Am. J. Hyg. 70: 303– 311.

59. Gelfand, H. M.,, D. R. LeBlanc,, and L. Potash. 1959. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am. J. Hyg. 70: 312– 327.

60. Gelfand, H. M.,, L. Potash,, and D. R. LeBlanc. 1959. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. JAMA 170: 2039– 2048.

61. Ghendon, Y. U. Z.,, and I. I. Sanakoyeva. 1961. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in person after naturally and experimentally acquired immunity. Acta Virol. (Prague) 5: 265– 273.

62. Greenberg, M.,, H. Abramson,, and H. M. Cooper. 1952. The relation between recent injections and paralytic poliomyelitis in children. Am. J. Public Health 42: 142.

63. Grist, N. R.,, and E. J. Bell. 1970. Enteroviral etiology of the paralytic poliomyelitis syndrome. Arch. Environ. Health 21: 382.

64. Halsey, N.,, and A. Galazka. 1985. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull. WHO. 63: 1151– 1169.

65. Hammon, W. M.,, L. I. Coriell,, and J. Stokes, Jr. 1952. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. JAMA 150: 139.

66. Hammon, W. M.,, L. L. Coriell,, P. F. Wehrle,, and J. J. Stokes. 1953. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. JAMA 151: 1272– 1285.

67. Hammon, W. M.,, and E. M. Izumi. 1942. Poliomyelitis mouse neutralization test, applied to acute and convalescent sera. Proc. Soc. Exp. Biol. Med. 49: 242.

68. Hammon, W. M.,, and E. C. Roberts. 1948. Serum neutralizing antibodies to the infecting strain of virus in poliomyelitis patients. Proc. Soc. Exp. Biol. Med. 69: 256– 258.

69. Hanlon, P.,, L. Hanlon,, V. Marsh, et al. 1987. Serological comparisons of approaches to polio vaccination in The Gambia. Lancet i: 800– 801.

70. Hardy, G. E.,, C. C. Hopkins,, and C. C. Linneman. 1970. Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. Pediatrics 45: 444– 448.

71. Harjulehto, T.,, T. Aro,, T. Hovi,, and L. Saxen. 1989. Congenital malformations and oral poliovirus vaccination during pregnancy. Lancet i: 771– 772.

72. Heine, J. 1940. Beobachtungen über Lähmungszustände der unteren Extremitäten und deren Behandlung. Köhler, Stuttgart, Germany.

73. Henderson, D. A.,, J. J. Witte,, L. Morris,, and A. D. Langmuir. 1964. Paralytic disease associated with oral poliovaccines. JAMA 190: 153– 160.

74. Henderson, R. H. 1984. The Expanded Programme on Immunization of the World Health Organization. Rev. Infect. Dis. 6( 2): 475– 479.

75. Henry, J. L.,, E. S. Jaikaran,, and J. R. Davies. 1966. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J. Hyg. 64: 105– 120.

76. Hill, A. B.,, and J. Knowelden. 1950. Inoculation and poliomyelitis: a statistical investigation in England and Wales in 1949. Br. Med. J. 2: 1.

77. Hinman, A. R.,, J. P. Koplan,, W. A. Orenstein,, E. W. Brink,, and B. M. Nkowane. 1988. Live or inactivated poliovirus vaccine: an analysis of the benefits and risks. Am. J. Public Health 78: 291– 295.

78. Horstmann, D. M. 1949. Clinical aspects of acute poliomyelitis. Am. J. Med. 6: 592.

79. Horstmann, D. M. 1950. Acute poliomyelitis. Relation of physical activity at the time of onset to the course of the disease. JAMA 142: 236.

80. Horstmann, D. M. 1952. Poliomyelitis in the blood of orally infected monkeys and chimpanzees. Proc. Soc. Exp. Biol. Med. 79: 417.

81. Horstmann, D. M. 1985. The poliomyelitis story: a scientific hegira. Yale J. Biol. Med. 58: 7990.

82. Horstmann, D. M.,, and R. W. McCollum. 1953. Poliomyelitis virus in human blood during the "minor" illness and asymptomatic infection. Proc. Soc. Exp. Biol. Med. 82: 434.

83. Horstmann, D. M.,, R. W. McCollum,, and A. D. Mascola. 1954. Viremia in human poliomyelitis. J. Exp. Med. 99: 355– 369.

84. Horstmann, D. M.,, E. M. Opton,, and R. Klemperer. 1964. Viremia in infants vaccinated with oral poliovirus vaccine (Sabin). Am. J. Hyg. 79: 47.

85. Horstmann, D. M.,, and J. R. Paul. 1947. The incubation period in human poliomyelitis and its implications. JAMA 135: 11.

86. Howe, H. A.,, and D. Bodian. 1941. Poliomyelitis in the chimpanzee; a clinical pathological study. Bull. Johns Hopkins Hosp. 69: 149– 181.

87. Hull, H. F.,, N. A. Ward,, B. P. Hull,, J. B. Milstien,, and C. de Quadros. 1994. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343: 1331– 1337.

88. Idris, M. Z.,, A. Mathur,, P. Sharma,, U. C. Chaturvedi,, and N. L. Sharma. 1980. Oral polio vaccination and factors affecting its efficacy. Indian J. Med. Res. 71: 671– 678.

89.Institute of Medicine, National Academy of Sciences. 1988. An Evaluation of Poliomyelitis Vaccine Policy Options. National Academy of Sciences, Washington, D.C.

90. John, T. J. 1976. Antibody response of infants in tropics to five doses of oral polio vaccine. Lancet i: 812.

91. John, T. J. 1984. Poliomyelitis in India: prospects and problems of control. Rev. Infect. Dis. 6( 2): 438– 441.

92. John, T. J.,, and S. Christopher. 1975. Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. Am. J. Epidemiol. 102: 414– 421.

93. John, T. J.,, and S. Christopher. 1975. Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take and antibody response. Am. J. Epidemiol. 102: 422– 428.

94. John, T. J.,, L. V. Devarajan,, L. Luther,, and P. Vijayarathnam. 1976. Effect of breast-feeding on seroresponse of infants to oral poliovirus vaccination. Pediatrics 57: 47– 53.

95. John, T. J.,, and P. Jayabal. 1972. Oral polio vaccination of children in the tropics: I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol. 96: 263– 269.

96. Johnson, R. T. 1984. Late progression of poliomyelitis paralysis: discussion of pathogenesis. Rev. Infect. Dis. 6( 2): S568– S569.

97. Jubelt, B.,, G. Gallez-Hawkins,, and O. Narayan. 1980. Pathogenesis of human poliovirus infection in mice. II. Age dependency of paralysis. J. Neuropathol. Exp. Neurol. 39: 149.

98. Kessel, J. F.,, and F. D. Stimpert. 1940. Attempts to transmit poliomyelitis virus to rodents. Proc. Soc. Exp. Biol. Med. 45: 665– 667.

99. Kim-Farley, R. J.,, K. J. Bart,, L. B. Schonberger, et al. 1984. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus. Lancet ii: 1315– 1317.

100. Kim-Farley, R. J.,, G. Rutherford,, P. Lichfield, et al. 1984. Outbreak of paralytic poliomyelitis, Taiwan. Lancet ii: 1322– 1324.

101. Kling, C.,, G. Levaditi,, and P. Lepine. 1929. La pénétration du virus poliomyélitique à travers la muqueuse du tube digestif chez le singe et sa conservation dans l'eau. Bull. Acad. Med. ( Paris) 102: 158.

102. Kling, C.,, A. Petterson,, and W. Wernstedt. 1912. Experimental and pathological investigation. The presence of the microbe of infantile paralysis in human beings. Commun. Inst. Med. Etat Stockholm 3: 5.

103. Kolmer, J. A. 1935. Susceptibility and immunity in relation to vaccination in acute anterior poliomyelitis. JAMA 105: 1956– 1962.

104. Koprowski, H. 1956. Immunization against poliomyelitis with living attenuated virus. Am. J. Trop. Med. Hyg. 5: 440– 452.

105. Koprowski, H.,, G. A. Jervis,, and T. W. Norton. 1952. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. Am. J. Hyg. 55: 108– 126.

106. Kramer, S. D.,, W. L. Aycock,, C. I. Soloman,, and C. L. Thenebe. 1932. Convalescent serum therapy in preparalytic poliomyelitis. N. Engl. J. Med. 206: 432.

107. Kramer, S. D.,, B. Hoskwith,, and L. H. Grossman. 1939. Detection of the virus of poliomyelitis in the nose and throat and gastrointestinal tract of human beings and monkeys. J. Exp. Med. 69: 49– 67.

108. Krugman, R. D.,, G. E. Hardy,, and C. Sellers. 1977. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics 60: 80– 82.

109. Landsteiner, K.,, C. Levaditi,, and C. Pastia. 1911. Etude expérimentale de la poliomyélite aiguë (maladie de Heine-Medin). Ann. Inst. Pasteur 25: 805.

110. Landsteiner, K.,, and E. Popper. 1908. Mikroscopische Praparate von einem Mensch-lichen und zwei Affenrückemarken. Wein Klin. Wochenschr. 21: 1830.

111. Lasch, E. E.,, Y. Abed,, K. Abdulla, et al. 1984. Succesful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev. Infect. Dis. 6: 467– 470.

112. Lasch, E. E.,, Y. Abed,, O. Marcus,, C. B. Gerichter,, and J. L. Melnick. 1986. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country— five years after. Dev. Biol. Stand. 65: 137– 143.

113. Leake, J. P. 1935. Poliomyelitis following vaccination against the disease. JAMA 105: 2152.

114. Leegaard, C. 1914. Die akute Poliomyelitis in Norwegen. Dtsch. Z. Nervenheilkd. 53: 145– 262.

115. Lipson, M. J.,, F. C. Robbins,, and W. A. Woods. 1956. The influence of vaccination upon intestinal infection of family contacts of poliomyelitis patients. J. Clin. Invest. 35: 722.

116. Lockhart, J. G. 1837. Memoirs of the Life of Sir Walter Scott, Bart. Carey Lean and Blanchard, Philadelphia.

117. Lopez, C.,, W. D. Biggar,, and B. H. Park. 1974. Nonparalytic poliovirus infections in patients with severe combined immunodeficiency disease. J. Pediatr. 84: 497– 502.

118. Lovett, R. W. 1916. The Treatment of Infantile Paralysis. P. Blakeston's Sons, Philadelphia.

119. Marine, W. M.,, T. D. Y. Chin,, and C. R. Gravelle. 1962. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. Am. J. Hyg. 76: 173– 195.

120. Mauler, R.,, and H. Gruschkau. 1978. On stability of oral poliovirus vaccines. Dev. Biol. Stand. 41: 267– 270.

121. McBean, A. M.,, and J. F. Modlin. 1987. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine use in the United States. Pediat. Infect. Dis. J. 6: 881– 887.

122. McBean, A. M.,, M. L. Thorns,, and P. Albrecht. 1988. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am. J. Epidemiol. 128: 615– 628.

123. McClure, G.Y.,, and A. D. Langmuir. 1942. Search for carriers in an outbreak of acute anterior poliomyelitis in a rural community. Am. J. Hyg. 35: 285.

124. McKinney, R. E.,, S. L. Katz,, C. M. Wilfert,, R. E. McKinney, Jr.,, S. L. Katz,, and C. M. Wilfert. 1987. Chronic enteroviral meningoencephalitis in agammaglobu-linemic patients. Rev. Infect. Dis. 9: 334– 356.

125. Melnick, J. L. 1947. Fly-abatement studies in urban poliomyelitis epidemics during 1945. Public Health Rep. 62: 910– 922.

126. Melnick, J. L. 1947. Poliomyelitis virus in urban sewage in epidemic and nonepidemic times. Am. J. Hyg. 45: 240– 253.

127. Melnick, J. L. 1981. Combined use of live and killed vaccines to control poliomyelitis in tropical areas. Dev. Biol. Stand. 47: 265– 273.

128. Melnick, J. L.,, and N. Ledinko. 1951. Social serology: antibody levels in a normal young population during an epidemic of poliomyelitis. Am. J. Hyg. 54: 354.

129. Minor, P.,, G. Dunn,, N. Begg,, A. Murdin,, J. Thipphawong,, and L. Barreto. 1993. Poliovirus vaccination schedules and reversion to virulence, abstr. 1426. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother.

130. Minor, P. D.,, A. John,, M. Ferguson,, and J. P. Icenogle. 1986. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J. Gen. Virol. 67: 693– 706.

131. Minor, T. E.,, C. I. Allen,, A. A. Tsiatis,, D. B. Nelson,, and D. J. D'Alessio. 1981. Human infective dose determinations for oral poliovirus type 1 vaccine in infants. J. Clin. Microbiol. 13: 388– 389.

132. Modlin, J. F.,, I. M. Onorato,, A. M. McBean, et al. 1990. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine. Am. J. Dis. Child. 144: 480– 484.

133. Morinere, B. J.,, F. P. L. van Loon,, P. H. Rhodes, et al. 1993. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 341: 1545– 1550.

134. Myaux, J. A.,, L. Unicomb,, A. Uzma, et al. Diarrhoea contributes to a poor serological response to oral polio vaccination. Submitted for publication.

135. Nathanson, N.,, and J. R. Martin. 1979. The epidemiology of poliomyelitis: enigmas surrounding its appearance and disappearance. Am. J. Epidemiol. 110: 672.

136. Netter, A. 1915. La serotherapie de la poliomyelite; nos resultats chez 30 malades; indications, techniques; incidents possibles. Gaz. Med. Paris 86: 88.

137. Netter, A.,, and C. Levaditi. 1910. Action microbicide exercee sur la virus de la poliomyelite aigue par le serum des sujets anterieurement atteints de paralysie infantile; sa constatation dans le serum d'un sujet qui a presente une forme abortive. C. R. Soc. Biol. (Paris) 68: 855.

138. Nishio, O.,, Y. Ishihara. and K. Sakae. 1984. The trend of acquired immunity with live poliovirus vaccine and the effect of revac-cination: follow-up of vaccinees for ten years. J. Biol. Stand. 12: 1– 10.

139. Nkowane, B. M.,, S. C. F. Wassilak,, and W. A. Orenstein. 1987. Vaccine-associated paralytic poliomyelitis: United States: 1973 through 1984. JAMA 257: 1335– 1340.

140. Ofusu-Amaah, S. 1984. The challenge of poliomyelitis in tropical Africa. Rev. Infect. Dis. 6( 2): 318– 320.

141. Ogra, P. L. 1968. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N. Engl. J. Med. 279: 893– 900.

142. Ogra, P. L. 1984. Mucosal immune response to poliovirus vaccines in childhood. Rev. Infect. Dis. 6( 2): S361– S368.

143. Ogra, P. L.,, and D. T. Karzon. 1971. Formation and function of poliovirus antibody in different tissues. Prog. Med. Virol. 13: 157.

144. Onorato, I. M.,, J. F. Modlin,, A. M. McBean,, M. L. Thorns,, G. A. Losonsky,, and R. Bernier. 1991. Mucosal immunity induced by enhanced potency IPV and OPV J. Infect. Dis. 163: 1– 6.

145. Osier, W. 1892. Principles and Practice of Medicine. Young and Pentland, Edinburgh.

146. Paffenbarger, R. S. 1957. The effect of prior tonsillectomy on incidence and clinical type of acute poliomyelitis. Am. J. Hyg. 66: 131.

147. Paffenbarger, R. S.,, and J. Watt. 1953. Poliomyelitis in Hidalgo County, Texas, 1948. Epidemiologic observations. Am. J. Hyg. 58: 269– 287.

148. Paffenbarger, R. S.,, and V. D. Wilson. 1955. Previously tonsillectomy and current pregnancy as they affect risk of poliomyelitis. Ann. N.Y.Acad. Sci. 61: 856– 868.

149.Pan American Health Organization. 1985. Polio outbreak in Honduras. Expanded Programme Immunization Newsl. 7: 1– 4.

150.Pan American Health Organization. 1986. Polio in Brazil's northeast. Expanded Programme Immunization Newsl. 8: 3– 4.

151. Patriarca, P. A.,, F. Laender,, G. Palmeira, et al. 1988. Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet 1: 429– 433.

152. Patriarca, P. A.,, P. F. Wright,, and T. J. John. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev. Infect. Dis. 13: 926– 939.

153. Paul, J. P. 1951. Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan Eskimos. Am. J. Hyg. 54: 275– 285.

154. Paul, J. R. 1971. History of Poliomyelitis. Yale University Press, New Haven, Conn.

155. Paul, J. R.,, and J. T. Riordan. 1950. Observations on serological epidemiology. Am. J. Hyg. 52: 202– 212.

156. Paul, J. R.,, and J. D. Trask. 1933. A comparative study of recently isolated human strains and a passage strain of poliomyelitis virus. J. Exp. Med. 58: 513– 529.

157. Paul, J. R.,, and J. D. Trask. 1935. The neutralization test in poliomyelitis; comparative results with four strains of the virus. J. Exp. Med. 61: 447– 464.

158. Paul, J. R.,, J. D. Trask,, and C. S. Culotta. 1939. Poliomyelitic virus in sewage. Science 90: 258– 259.

159. Peabody, F. W.,, G. Draper,, and A. R. Dochez. 1912. A Clinical Study of Acute Poliomyelitis. Monograph no. 4. Rockefeller Institute of Medical Research, New York.

160. Plotkin, S. A.,, M. Katz,, R. E. Brown,, and J. S. Pagano. 1966. Oral poliovirus vaccination in newborn African infants. The inhibitory effect of breast-feeding. Am. J. Dis. Child. 111: 27– 30.

161. Pohl, J. F.,, and E. Kenny. 1943. The Kenny Concept of Infantile Paralysis and Its Treatment. Bruce, Minneapolis.

162. Prevots, D. R.,, R. W. Sutter,, P. M. Strebel,, R. E. Weibel,, and S. L. Cochi. 1994. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch. Pediatr. Adolesc. Med. 148: 479– 485.

163. Putnam, J. J.,, and E. W. Taylor. 1893. Is acute poliomyelitis unusually prevalent this season. Boston Med. Surg. J. 129: 509– 519.

164. Ramlow, J.,, M. Alexander,, and R. LaPorte. 1992. Epidemiology of the post-polio syndrome. Am. J. Epidemiol. 136: 769– 786.

165. Ren, R.,, and V. R. Rancaniello. 1992. Poliovirus spreads from muscle to the central nervous system by neural pathways. J. Infect. Dis. 166: 747– 752.

166. Rennels, M. 1994. Concurrent administration of oral rhesus rotavirus reassortant vaccines (at 4xl0 5pfu) and OPV did not result in significant immune interference, abstr. H62. Abstr. 34th Intersci. Conf. Antimicrob. Agents Chemother.

167. Richardson, G.,, R. Linkins,, and M. Eames. 1993. Immunogenicity of oral poliovirus vaccine (OPV) given in mass campaigns versus routine immunization programs, abstr. 1237. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother.

168. Risi, J. B. 1984. The control of poliomyelitis in Brazil. Rev. Infect. Dis. 6( 2): 400– 403.

169. Rissler, J. 1888. Zur Kenntniss der Veranderungen des Nervensystems bei Poliomyelitis anterior acuta. Nord. Med. Ark. 20: 1.

170. Robertson, H. E. 1962. Community-wide use of a "balanced" trivalent oral poliovirus vaccine (Sabin). Can. J. Public Health 53: 179– 191.

171. Robertson, S. E.,, H. P. Traverso,, J. A. Drucker, et al. 1988. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet i: 897– 899.

172.RockefellerFoundation. 1984. Protecting the World's Children: Vaccines and Immunization. Rockefeller Foundation, Bellagio, Italy.

173. Russell, W. R. 1947. Poliomyelitis: the preparalytic stage, and the effect of physical activity on the severity of paralysis. Br. Med. J. 2: 1023.

174. Russell, W. R. 1949. Paralytic poliomyelitis: the early symptoms, and the effect of physical activity on the course of disease. Br. Med. J. 1: 465.

175. Russell, W. R.,, and M. Fischer-Williams. 1954. Recovery of muscular strength after poliomyelitis. Lancet i: 330.

176. Sabin, A. B. 1955. Behavior of chimpanzee-avirulent poliomyelitis viruses in experimentally infected human volunteers. Am. J. Med. Sci. 230: 1.

177. Sabin, A. B. 1957. Properties and behavior of orally administered attenuated poliovirus vaccine. JAMA 164: 1216– 1223.

178. Sabin, A. B. 1984. Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev. Infect. Dis. 6( 2): 391– 396.

179. Sabin, A. B. 1985. Oral polio vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151: 420– 436.

180. Sabin, A. B. 1987. Commentary: is there a need for a change in poliomyelitis immunization policy? Pediatr. Infect. Dis. J. 6: 887– 889.

181. Sabin, A. B.,, and P. K. Olitsky. 1936. Cultivation of poliovirus in vitro in human embryonic nervous tissue. Proc. Soc. Exp. Biol. Med. 34: 357– 359.

182. Sabin, A. B.,, and R. Ward. 1941. Flies as carriers in human poliomyelitis virus. Science 94: 590.

183. Salk, D. 1980. Eradication of poliomyelitis in the United States. II. Experience with killed poliovirus vaccine. Rev. Infect. Dis. 2: 243– 257.

184. Salk, J. 1987. Commentary: poliomyelitis vaccination—choosing a wise policy? Pediatr. Infect. Dis. J. 6: 889– 893.

185. Salk, J. E. 1953. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. JAMA 151: 1081– 1098.

186. Schaap, G. J. P.,, H. Bijkerk,, and R. A. Coutinho. 1984. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog. Med. Virol. 29: 124– 140.

187. Schoub, B. D. 1992. Poliomyelitis outbreak in Natal/KwaZulu, South Africa, 1987-1988. II. Immunity aspects. Trans. R. Soc. Trop. Med. Hyg. 86: 83– 85.

188. Shindarov, L. M.,, M. P. Chumakov,, and M. K. Voroshilova. 1979. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J. Hyg. Epidemiol. Microbiol. Immunol. 23: 284.

189. Siegel, M.,, and M. Greenberg. 1956. Poliomyelitis in pregnancy: effect on fetus and newborn infant. J. Pediatr. 49: 280– 288.

190. Simoes, E. A.,, and T. J. John. 1986. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J. Biol. Stand. 14: 127– 131.

191. Simoes, E. A. P.,, B. Padmini,, M. C. SteinhofF,, M. Jadhav,, and T. J. John. 1995. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am. J. Dis. Child. 139: 977– 980.

192. Sokhey, J.,, C. K. Gupta,, B. Sharma,, and H. Singh. 1988. Stability of oral polio vaccine at different temperatures. Vaccine 6: 12– 13.

193. Stanway, G.,, P. J. Hughes,, R. C. Mountford, et al. 1984. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/ Leon 12alb. Proc. Natl. Acad. Sci. USA 81: 1539– 1543.

194. Stickle, G. 1964. Observed and expected poliomyelitis in the United States, 1958-1961. Am. J. Public Health 1964: 1222– 1229.

195. Strebel, P. M.,, R. W. Sutter,, and S. L. Cochi. 1992. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14: 568– 579.

196. Sutter, R. W. 1991. An outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 338: 715– 720.

197. Sutter, R. W. 1992. Attributable risk of DTP (diphtheria and tetanus toxins and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. J. Infect. Dis. 165: 444– 449.

198. Swartz, T. A.,, E. Ben-Porath,, Z. Ben-Yshai, et al. 1981. A controlled trial with inactivated poliovaccine. Dev. Biol. Stand. 47: 199– 206.

199. Swartz, T. A.,, M. Roumiantzeff,, L. Peyron, et al. 1986. Use of a combined DTP-polio vaccine in a reduced schedule. Dev. Biol. Stand. 65: 159– 166.

200. Taylor, E.,, and H. L. Amoss. 1917. Carriage of the virus of poliomyelitis, with subsequent development of the infection. J. Exp. Med. 26: 745– 754.

201.The Committee on Typing of the National Foundation for Infantile Paralysis. 1951. A cooperative program for the typing of one hundred strains. Am. J. Hyg. 54: 191– 274.

202. Tisdall, F. F.,, A. Brown,, R. D. deFries,, M. A. Ross,, and A. H. Sellers. 1937. Zinc sulphate nasal spray in the prophylaxis of poliomyelitis; observations of a group of 4, 713 children age 3-10 years, during an epidemic in Toronto. Can. J. Public Health 28: 523.

203. Trask, J. D.,, A. J. Vignec,, and J. R. Paul. 1937. Isolation of poliomyelitis virus from human stools. Proc. Soc. Exp. Biol. Med. 38: 147– 149.

204. Trueta, J.,, and R. Hodes. 1954. Provoking and localizing factors in poliomyelitis. Lancet 1: 998.

205. Turner, T. B.,, L. E. Young,, and E. S. Maxwell. 1945. Mouse-adapted Lansing strain of poliomyelitis virus: neutralizing antibodies in serum of healthy children. Am. J. Hyg. 42: 119– 127.

206. Underwood, M. 1789. A Treatise on Diseases of Children with General Directions for the Management of Infants from the Birth, 2nd ed. Mathews, London.

207.VermontStateDepartmentofPublicHealth. 1924. Infantile Paralysis in Vermont. Vermont Printing Co., Brattleboro.

208. Voroshilova, M. K.,, and M. P. Chumakov. 1959. Poliomyelitis-like properties of AB-IV-coxsackie A7 group of viruses. Prog. Med. Virol. 2: 106.

209. Ward, R.,, D. M. Horstmann,, and J. L. Melnick. 1946. The isolation of poliovirus from human extra-neural sources; search for virus in the blood of patients. J. Clin. Invest. 25: 284– 286.

210. Ward, R.,, J. L. Melnick,, and D. M. Horstmann. 1945. Poliomyelitis virus in fly-contaminated food collected at an epidemic. Science 101: 491– 493.

211. Wehrle, P. F.,, O. Carbonaro,, and P. A. Day. 1961. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics 27: 762– 764.

212. Wehrle, P. F.,, R. Reichert,, and O. Carbonaro. 1958. Influence of prior active immunization on the presence of poliomyelitis virus in the pharynx and stools of family contacts of patients with paralytic poliomyelitis. Pediatrics 21: 353– 361.

213. Weinstein, L.,, W. L. Aycock,, and R. F. Feemster. 1951. Relation of sex, pregnancy, and menstruation to susceptibility in poliomyelitis. N. Engl. J. Med. 245: 54.

214. Weinstein, L.,, A. Shelokov,, and R. Seltser. 1952. A comparison of the clinical features of poliomyelitis in adults and children. N. Engl. J. Med. 246: 296.

215. Wernstedt, W. 1912. Some epidemiologic experiences from the great epidemic of infantile paralysis which occurred in Sweden in 1911. Commun. Inst. Med. Etat Stockholm 3: 235– 267.71.

216. WHO Collaborative Study Group on Oral Poliovirus Vaccine. 1992. Effect of diarrhea on seroconversion to oral poliovirus vaccine, abstr. 1401. Program Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother.

217. WHO Collaborative Study Group on Oral Poliovirus Vaccine. 1992. A randomized trial of alternative formulations of oral poliovirus vaccine (OPV) in Brazil and The Gambia, abstr. 916. Program Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother.

218.WHO Collaborative Study Group on Oral Poliovirus Vaccine. 1993. Effect of secondary spread of oral polio vaccine (OPV) virus on seroconversion rates to poliovirus in Brazil and The Gambia, abstr. 1428. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother.

219. Wickman, I. 1907. Beitrage zur Kenntnis der Heine-Medinschen Krankheit (Poliomyelitis acuta und verwandter Erkrankungen). Karger, Berlin.

220. World Health Organization. 1988. Global eradication of poliomyelitis by the year 2000. Weekly Epidemiol. Rec. W.H.O. 63: 161– 162.

221. Wright, P. F.,, R. J. Kim-Farley,, C. A. de Quadros, et al. 1991. Strategies for the global eradication of poliomyelitis by the year 2000. N. Engl. J. Med. 325: 1774– 1779.

222. Wyatt, H. V. 1973. Poliomyelitis in hypo-gammaglobulinemics. J. Infect. Dis. 128: 802.

223. Wyatt, H. V. 1975. Risk of live poliovirus in immunodeficient children. J. Pediatr. 87: 152.